论文部分内容阅读
Novartis公司的抗CD25单克隆抗体basiliximab（商品名Simulec）在瑞士获得许可，这是本品首次在世界范围内获得许可用于预防肾移植时的急性移植物排斥。公司认为本品较Hoffmann－LaRoche公司最近在美国和瑞士上市的人单克隆抗体da－clizumab（acliximab，商品名ZenapaX）更具优
Novartis’s anti-CD25 monoclonal antibody basiliximab (Simulec) is licensed in Switzerland and is the first time this product has been licensed worldwide for the prevention of acute graft rejection in kidney transplant. The company believes this product is superior to Hoffmann-LaRoche’s recently introduced human monoclonal antibody da-clizumab (acliximab, trade name ZenapaX) in the U.S. and Switzerland